<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621278</url>
  </required_header>
  <id_info>
    <org_study_id>Mental Health Child to Adult</org_study_id>
    <nct_id>NCT05621278</nct_id>
  </id_info>
  <brief_title>The Longitudinal Study of Mental Health in Child to Adult</brief_title>
  <official_title>A National Longitudinal Study of Mental Health in Child to Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess mental health, cognitive development, positive resources,&#xD;
      enviromental factors of school-age children, adolescents and adults in China. The study will&#xD;
      recruit teachers, students and students' parents through schools. Scales and behavioral&#xD;
      experiments will be applied for assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Irritability</measure>
    <time_frame>1 month</time_frame>
    <description>A 17-item irritability measurement scale, Peking irritability scale, measuring impulsive emotions, thoughs and behaviors on a 5-point Likert scale (score from 1 to 5, and total score vary from 17 to 85). Higher score represents higher irritability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotion aviodance</measure>
    <time_frame>1 month</time_frame>
    <description>A 36-item emotion aviodance scale, Peking alexithymia scale, measuring thoughts and behaviors preventing from feeling or recognizing negative emotions on a 5-point Likert scale (score from 1 to 5, and total score vary from 36 to 180). Higher score represents more emotion aviodance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression for adults</measure>
    <time_frame>2 weeks</time_frame>
    <description>The 9-item patient health questionnaire (PHQ-9) for adults (score from 0 to 3, and total score vary from 0 to 27). Higher score represents worse depression symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression for adolescents and children</measure>
    <time_frame>2 weeks</time_frame>
    <description>Children's depression inventory (CDI) for adolescents and children (score from 0 to 2, and total score vary from 0 to 54). Higher score represents worse depression symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generalized anxiety disorder</measure>
    <time_frame>2 weeks</time_frame>
    <description>The generalized anxiety disorder-7 scale (GAD-7) for adults, adolescents and children (scored from 0 to 3, and total score from 0 to 21). Higher score represents worse anxiety symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety and depression for adolescents and children</measure>
    <time_frame>2 weeks</time_frame>
    <description>The Revised Child Anxiety and Depression Scale (RCADS) for adolescents and children (scored from 0 to 3, and total score from 0 to 75). Higher score represents worse anxiety and depression symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PTSD for adults</measure>
    <time_frame>1 month</time_frame>
    <description>The PTSD Symptoms Scale-Interview for DSM-5 (PSSI-5) for adults (socre from 0 to 4, and total score vary from 0 to 80). Higher score represents worse PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PTSD for adolescents and children</measure>
    <time_frame>1 month</time_frame>
    <description>The Child PTSD Symptom Scale for DSM-5 (CPSS-5) for adolescents and children (socre from 0 to 4, and total score vary from 0 to 80). Higher score represents worse PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NSSI</measure>
    <time_frame>1 year</time_frame>
    <description>The non-suicidal self-injury assessment tool (NSSI-AT-Severity) for adolescent and children (total score vary from 5 to 16). Higher score represents worse self-injury situation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicide</measure>
    <time_frame>1 year</time_frame>
    <description>The suicidal behaviors questionnaire-revised (SBQ-R) for adolescent and children (total score vary from 3 to 18). Higher score represents higher suicide risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotion recognition</measure>
    <time_frame>Half year</time_frame>
    <description>The Morph task for adolescent to examinate the emotion recognition capability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Excutive function</measure>
    <time_frame>Half year</time_frame>
    <description>The Go/Nogo task for adolescent to examinate inhibition funciton.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400000</enrollment>
  <condition>Mental Health Wellness 1</condition>
  <condition>Cognitive Function</condition>
  <arm_group>
    <arm_group_label>Children</arm_group_label>
    <description>Grade 5 and grade 6 students (aged 9-12) in primary school.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescent</arm_group_label>
    <description>Grade 7 to grade 12 students (aged 12-18) in middle school and high school.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Students' teachers</arm_group_label>
    <description>School Teachers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Students' parent</arm_group_label>
    <description>Parents of students mentioned above.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Students from 5 grade to 12 grade and their parents and teachers in Chinese schools.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Students from 5 grade to 12 grade, their parents and teachers&#xD;
&#xD;
          2. able to read, answer questionnaires and complete experiments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        a. Students who suspend schooling.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zang Yinyin, PhD</last_name>
    <phone>+86 15553201610</phone>
    <email>yinyin.zang@pku.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100871</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yinyin Zang</last_name>
      <phone>+86-010-62756953</phone>
      <email>yinyin.zang@pku.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yinyin Zang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>September 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 12, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 12, 2022</last_update_submitted>
  <last_update_submitted_qc>November 12, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>YinyinZang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

